By leveraging tumor‐infiltrating GITR+ Treg as a novel biomarker, clinicians can more accurately assess survival prospects for patients whose prognoses are not adequately captured by serum CA19‐9. This evidence concerns the gene TNFRSF18 and neoplasm.